Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PETS 
PetMed Express Inc (PETS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: PETS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.75
1 Year Target Price $2.75
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.41% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 54.85M USD | Price to earnings Ratio - | 1Y Target Price 2.75 |
Price to earnings Ratio - | 1Y Target Price 2.75 | ||
Volume (30-day avg) 2 | Beta 0.74 | 52 Weeks Range 2.42 - 6.85 | Updated Date 11/10/2025 |
52 Weeks Range 2.42 - 6.85 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date 2025-10-27 | When - | Estimate 0.07 | Actual - |
Profitability
Profit Margin -2.76% | Operating Margin (TTM) -27.51% |
Management Effectiveness
Return on Assets (TTM) -3.25% | Return on Equity (TTM) -6.9% |
Valuation
Trailing PE - | Forward PE 17.92 | Enterprise Value 1135608 | Price to Sales(TTM) 0.24 |
Enterprise Value 1135608 | Price to Sales(TTM) 0.24 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 0.17 | Shares Outstanding 21015559 | Shares Floating 13659402 |
Shares Outstanding 21015559 | Shares Floating 13659402 | ||
Percent Insiders 31.41 | Percent Institutions 37.23 |
Upturn AI SWOT
PetMed Express Inc
Company Overview
History and Background
PetMed Express, Inc. (PetMeds) was founded in 1996 by Marc Puleo. It began as a mail-order catalog and transitioned to an online retailer of pet medications and supplies. Over the years, it expanded its product offerings and focused on building a loyal customer base.
Core Business Areas
- Pet Medications: Prescription and non-prescription medications for dogs, cats, and horses, including flea and tick preventatives, heartworm preventatives, and pain relievers.
- Pet Supplies: A range of pet supplies such as food, supplements, grooming products, and accessories.
Leadership and Structure
Mendo Akdag is the current CEO. The company has a board of directors and operates with a standard corporate structure.
Top Products and Market Share
Key Offerings
- Flea and Tick Preventatives: Includes products like Frontline, Advantage, and Revolution. This is a significant revenue generator. Competitors include Chewy, Amazon, and veterinary clinics. Estimated Market Share for Flea/Tick treatment for Petmeds is roughly 5% of the total market. Competitors include Zoetis, Elanco Animal Health, Merck Animal Health.
- Heartworm Preventatives: Includes products like Heartgard and Interceptor. Competitors include Chewy, Amazon, and veterinary clinics. Estimated Market Share for Heartworm treatment for Petmeds is roughly 5% of the total market. Competitors include Zoetis, Elanco Animal Health, Merck Animal Health.
- Pet Food and Treats: Selection of various pet food brands and treats. Competitors include Chewy, Petco, and Petsmart.
Market Dynamics
Industry Overview
The pet medication and supply industry is growing, driven by increased pet ownership and rising spending on pet care. The industry is increasingly competitive, with both online and brick-and-mortar retailers vying for market share.
Positioning
PetMeds is positioned as a convenient online retailer of pet medications and supplies, offering competitive prices and home delivery. Its competitive advantages include its established brand reputation and focus on customer service.
Total Addressable Market (TAM)
The total addressable market for pet medications and supplies is estimated to be over $30 billion. PetMed Express is positioned to capture a share of this market through its online platform and focus on prescription medications.
Upturn SWOT Analysis
Strengths
- Established brand reputation
- Online platform for convenient shopping
- Focus on prescription medications
- Strong customer service reputation
Weaknesses
- Dependence on third-party suppliers
- Highly competitive market
- Potential for regulatory changes impacting prescription medication sales
- Declining active customer base
Opportunities
- Expanding product offerings
- Increasing market share through targeted marketing
- Partnerships with veterinary clinics
- International expansion
Threats
- Increased competition from online retailers like Chewy and Amazon
- Changes in consumer preferences
- Economic downturn impacting pet spending
- Potential regulations on online pet medication sales
Competitors and Market Share
Key Competitors
- CHWY
- AMZN
- VCA (Mars, Inc - Private)
- PETS
Competitive Landscape
PetMed Express faces significant competition from larger online retailers like Chewy and Amazon, as well as brick-and-mortar stores like Petco and Petsmart. Its competitive advantages include its established brand and focus on prescription medications, but it needs to innovate to stay ahead.
Growth Trajectory and Initiatives
Historical Growth: Historically, PetMed Express experienced strong growth due to the increasing popularity of online pet medication sales. However, growth has slowed in recent years due to increased competition.
Future Projections: Analyst estimates for future growth are mixed, reflecting uncertainty about the company's ability to compete effectively in the evolving pet medication market.
Recent Initiatives: Recent initiatives include expanding product offerings, investing in marketing, and improving customer service.
Summary
PetMed Express faces headwinds in a competitive market, and while their established brand and online presence are strengths, declining profitability is a concern. Increased competition and the need to adapt to changing consumer preferences pose significant challenges. To stay competitive, PetMed Express should look into diversifying its offerings and marketing and also look to international markets.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may not be precise. Financial data may be rounded and based on historical filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PetMed Express Inc
Exchange NASDAQ | Headquaters Delray Beach, FL, United States | ||
IPO Launch date 1999-04-26 | Independent Chairman of the Board, Interim CEO & President Ms. Leslie C. G. Campbell | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 173 | Website https://www.1800petmeds.com |
Full time employees 173 | Website https://www.1800petmeds.com | ||
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.